View in EDS

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Saved in:
Bibliographic Details
Title: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Authors: Frampton GM; Foundation Medicine Inc., Cambridge, Massachusetts. gframpton@foundationmedicine.com., Ali SM; Foundation Medicine Inc., Cambridge, Massachusetts., Rosenzweig M; Foundation Medicine Inc., Cambridge, Massachusetts., Chmielecki J; Foundation Medicine Inc., Cambridge, Massachusetts., Lu X; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California., Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee., Akimov M; Novartis Pharma AG, Basel, Switzerland., Bufill JA; Michiana Hematology-Oncology, PC, Mishawaka, Indiana., Lee C; University of North Carolina School of Medicine, Clinical Research, Thoracic Oncology Program, Chapel Hill, North Carolina., Jentz D; South Bend Medical Foundation, South Bend, Indiana., Hoover R; South Bend Medical Foundation, South Bend, Indiana., Ou SH; Division of Hematology-Oncology, Department of Medicine, University of California Irvine School of Medicine, Irvine, California., Salgia R; The University of Chicago School of Medicine, Chicago, Illinois., Brennan T; Foundation Medicine Inc., Cambridge, Massachusetts., Chalmers ZR; Foundation Medicine Inc., Cambridge, Massachusetts., Jaeger S; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Huang A; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Elvin JA; Foundation Medicine Inc., Cambridge, Massachusetts., Erlich R; Foundation Medicine Inc., Cambridge, Massachusetts., Fichtenholtz A; Foundation Medicine Inc., Cambridge, Massachusetts., Gowen KA; Foundation Medicine Inc., Cambridge, Massachusetts., Greenbowe J; Foundation Medicine Inc., Cambridge, Massachusetts., Johnson A; Foundation Medicine Inc., Cambridge, Massachusetts., Khaira D; Foundation Medicine Inc., Cambridge, Massachusetts., McMahon C; Foundation Medicine Inc., Cambridge, Massachusetts., Sanford EM; Foundation Medicine Inc., Cambridge, Massachusetts., Roels S; Foundation Medicine Inc., Cambridge, Massachusetts., White J; Foundation Medicine Inc., Cambridge, Massachusetts., Greshock J; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Schlegel R; Novartis Institutes for BioMedical Research, Cambridge, Massachusetts., Lipson D; Foundation Medicine Inc., Cambridge, Massachusetts., Yelensky R; Foundation Medicine Inc., Cambridge, Massachusetts., Morosini D; Foundation Medicine Inc., Cambridge, Massachusetts., Ross JS; Foundation Medicine Inc., Cambridge, Massachusetts., Collisson E; Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, San Francisco, California., Peters M; Novartis Pharma AG, Basel, Switzerland., Stephens PJ; Foundation Medicine Inc., Cambridge, Massachusetts., Miller VA; Foundation Medicine Inc., Cambridge, Massachusetts.
Source: Cancer discovery [Cancer Discov] 2015 Aug; Vol. 5 (8), pp. 850-9. Date of Electronic Publication: 2015 May 13.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101561693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2159-8290 (Electronic) Linking ISSN: 21598274 NLM ISO Abbreviation: Cancer Discov Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2159-8290
DOI:10.1158/2159-8290.CD-15-0285